Paul H Mathews

US Patent:

6838592, Jan 4, 2005

Filed:

Apr 28, 2000

Appl. No.:

09/560124

Inventors:

Ralph A. Nixon - Tarrytown NY, US
Anne M. Cataldo - Nanuet NY, US
Paul M. Mathews - Irvington NY, US

Assignee:

Nathan S. Kline Institute for Psychiatric Research - Orangeburg NY

International Classification:

G01N 3300
A01K 6700
A01K 67033
C12N 500
C12N 1563

US Classification:

800 3, 800 8, 800 9, 800 12, 800 18, 435325, 435455

Abstract:

The invention features methods for identifying compounds useful for the treatment of Alzheimer's disease.

US Patent:

7090987, Aug 15, 2006

Filed:

Apr 28, 2000

Appl. No.:

09/561582

Inventors:

Ralph A. Nixon - Tarrytown NY, US
Anne M. Cataldo - Nanuet NY, US
Paul M. Mathews - Irvington NY, US

International Classification:

C12Q 1/00
G01N 33/53

US Classification:

435 72, 435 4, 435 71

Abstract:

The invention features methods of diagnosing and treating a patient having Alzheimer's disease or other neuronal atrophy-associated dementia by determining or altering, respectively, the level of activity of pathways from the endoplasmic reticulum to lysosomes in the patient.

US Patent:

20050172344, Aug 4, 2005

Filed:

Nov 3, 2004

Appl. No.:

10/980922

Inventors:

Ottavio Arancio - New York NY, US
Paul Mathews - Irvington NY, US
Stephen Schmidt - Nutley NJ, US
Ralph Nixon - Tarrytown NY, US
Fortunato Battaglia - New York NY, US
Fabrizio Trinchese - Rome, IT
Shumin Liu - Tappan NY, US

International Classification:

A01K067/027
C12N005/06

US Classification:

800012000, 435354000

Abstract:

The present invention describes a dissociated cell culture system comprising cells of the hippocampus, one of the brain areas affected by Alzheimer's Disease (AD) or amyloid beta-related diseases. This culture system comprises hippocampal neuronal and glial cells from animal models of AD, particularly, but not limited to, double transgenic mice expressing both the human APP mutation (K670N:M671L) (mAPP), and the human PS1 mutation (M146L) (mPS1), and serves as a powerful tool for the screening and testing of compounds and substances, e.g., drugs, for their ability to affect, treat, or prevent AD or β-amyloid-related diseases. The effects of a test substance on the cells in this culture system can be quantitatively assessed to determine if the test substance affects the cells biochemically and/or electrophysiologically, and/or optically, and/or immunocytochemically. The present in vitro culture system is advantageous for AD drug screening, because it is rapid and efficient. By contrast, even in the fastest animal model of AD, pathology does not start before the end of the second month. If such in vivo animal models are used, it is necessary to wait at least the two month time duration or longer to test for drug efficacy for AD treatment or prevention. At the same time the present invention provides a tool for production of amyloid-beta that can be used for electrophysiological, behavioral, and toxicological studies.

US Patent:

20060101532, May 11, 2006

Filed:

Nov 8, 2004

Appl. No.:

10/983422

Inventors:

Ralph Nixon - Tarrytown NY, US
Anne Cataldo - Nanuet NY, US
Paul Mathews - Irvington NY, US

International Classification:

A01K 67/027

US Classification:

800012000, 800018000

Abstract:

The invention features methods for identifying compounds useful for the treatment of Alzheimer's disease. The invention also features methods of identifying genes involved in Alzheimer's disease pathology.

US Patent:

20100081613, Apr 1, 2010

Filed:

Mar 30, 2009

Appl. No.:

12/414160

Inventors:

Ottavio Arancio - New York NY, US
Daniela Puzzo - Catania, IT
Cristina Alberini - New York NY, US
Paul Mathews - Irvington NY, US

Assignee:

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY

International Classification:

A61K 38/16
A61P 25/00
A61P 25/28
A61P 25/16

US Classification:

514 12

Abstract:

The invention is directed to methods for enhancing memory by administering low doses of beta amyloid peptide. The invention also encompasses methods for increasing synaptic plasticity in a subject which comprises administering to the subject low doses of beta amyloid peptide.

US Patent:

59855819, Nov 16, 1999

Filed:

Jul 17, 1997

Appl. No.:

8/896176

Inventors:

Ralph A. Nixon - Tarrytown NY
Anne M. Cataldo - Nanuet NY
Benjamin H. Kao - New York NY
Paul M. Mathews - Irvington NY

Assignee:

The McLean Hospital Corporation - Belmont MA

International Classification:

G01N 3353
G01N 3348
G01N 33543

US Classification:

435 71

Abstract:

The invention provides a method of diagnosing Alzheimer's disease. The method utilizes presenilin-1, whose level is found to be substantially decreased in Alzheimer's patients. Included in the invention are diagnostic kits for Alzheimer's disease and methods of screening for effective therapeutics for the disease. The invention also provides a method of studying the function and regulation of presenilin-1 in brain by the use of primate retinoblastoma cells.